Literature DB >> 8113789

Antioxidant properties of bromocriptine, a dopamine agonist.

T Yoshikawa1, Y Minamiyama, Y Naito, M Kondo.   

Abstract

It has been suggested that free radicals may adversely influence the pathogenesis of Parkinson's disease. We conducted this study to determine whether bromocriptine, an agent widely used for treating parkinsonism, possesses antioxidant effects. Bromocriptine scavenged superoxide produced from a superoxide generating system (hypoxanthine-xanthine oxidase) by the spin-trapping method using electron spin resonance. Bromocriptine had a strong scavenging effect on the 5,5-dimethyl-1-pyrroline-N-oxide hydroxide signal produced from Fenton's reaction. Bromocriptine also attenuated the stable free radical diphenyl-p-picrylhydrazyl signal. This drug inhibited the autooxidation of rat brain homogenates in a dose-dependent manner in vitro. Autooxidation of brain homogenates collected from rats treated with bromocriptine (2.5 mg/kg, i.p., daily for 3 days) was significantly reduced as compared with values in untreated rat homogenates. These observations suggest that bromocriptine is a free radical scavenger and a potent antioxidant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113789     DOI: 10.1046/j.1471-4159.1994.62031034.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  26 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist.

Authors:  K Tanaka; I Miyazaki; N Fujita; M E Haque; M Asanuma; N Ogawa
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

3.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Manda, a fermented natural food, suppresses lipid peroxidation in the senescent rat brain.

Authors:  M Kawai; S Matsuura; M Asanuma; N Ogawa
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

Review 5.  Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Authors:  W D Le; J Jankovic
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 6.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

7.  Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on α2-adrenergic receptor in 3T3-L1 adipocyte cells.

Authors:  Rajib Mukherjee; Jong Won Yun
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

8.  Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells.

Authors:  R Maggio; M Armogida; M Scarselli; F Salvadori; B Longoni; C Pardini; A Chiarenza; S Chiacchio; F Vaglini; R Bernardini; A Colzi; G U Corsini
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

9.  Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.

Authors:  Yoshihisa Kitamura; Takashi Taniguchi; Shun Shimohama; Akinori Akaike; Yasuyuki Nomura
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

10.  Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.

Authors:  H Przuntek; D Welzel; M Gerlach; E Blümner; W Danielczyk; H J Kaiser; P H Kraus; H Letzel; P Riederer; K Uberla
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.